Abstract | OBJECTIVE: DESIGN: PARTICIPANTS: INTERVENTION: MAIN OUTCOME MEASURES: Intraocular inflammation, visual acuity (VA), neovascularization. Adverse effects of tacrolimus were documented. RESULTS: The posterior uveitis remained controlled in all patients while they were taking tacrolimus. Five of the six patients showed improvement, defined as improvement of two or more lines of Snellen acuity or a decrease in the binocular indirect ophthalmoscopy score (P < 0.05, Sign test). One patient with Behçet disease showed a marked improvement in best-corrected VA from 1/60 to 6/24. Two patients with Behçet disease showed a modest improvement in VA in the affected eye and had no disease activity in the other eye. The patient with microscopic polyangiitis was symptomatically improved, and there was no progression of the posterior uveitis. The patient with pars planitis had an improvement in VA from 6/18 to 6/9. The patient with retinal vasculitis showed partial regression of neovascularization on tacrolimus. Side effects were less troublesome than with cyclosporine. CONCLUSIONS:
|
Authors | C M Sloper, R J Powell, H S Dua |
Journal | Ophthalmology
(Ophthalmology)
Vol. 106
Issue 4
Pg. 723-8
(Apr 1999)
ISSN: 0161-6420 [Print] United States |
PMID | 10201592
(Publication Type: Case Reports, Clinical Trial, Journal Article)
|
Chemical References |
- Immunosuppressive Agents
- Cyclosporine
- Tacrolimus
|
Topics |
- Adolescent
- Adult
- Cyclosporine
(therapeutic use)
- Female
- Fundus Oculi
- Humans
- Immunosuppressive Agents
(adverse effects, therapeutic use)
- Male
- Middle Aged
- Safety
- Tacrolimus
(adverse effects, therapeutic use)
- Uveitis, Posterior
(drug therapy, physiopathology)
- Vision, Binocular
(physiology)
- Visual Acuity
(physiology)
|